{"success":true,"data":{"pressRelease":{"id":"167546","rtpr_id":"nGNX9gcm9l-20261013","ticker":"WVE","exchange":"NASDAQ","all_tickers":["WVE"],"title":"Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference","author":"Globe Newswire","published_at":"2026-10-13T12:30:00.158Z","article_body":"CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences,\nInc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health,\ntoday announced that Paul Bolno, MD, MBA, President and Chief Executive\nOfficer, is scheduled to participate in the “RNA Medicines: Next-Generation\nRNA Therapeutics” panel at Chardan’s 10(th) Annual Healthcare Conference\nin New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET.\n\nA live webcast of the panel can be accessed by visiting “Investor Events”\non the Investors section of the Wave Life Sciences website:\nhttps://ir.wavelifesciences.com/events-publications/events. A replay of this\npanel will be archived and available on the site for a limited time following\nthe event.\n\nAbout Wave Life Sciences\nWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health.\nWave’s PRISM® platform combines multiple RNA medicine modalities, chemistry\ninnovation, and deep insights in human genetics to deliver scientific\nbreakthroughs that treat both rare and common disorders. Its toolkit of\nRNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers),\nprovides Wave with unmatched capabilities for designing and sustainably\ndelivering candidates that optimally address disease biology. Wave’s\npipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency\n(WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes\nclinical programs in Duchenne muscular dystrophy and Huntington’s disease,\nas well as several preclinical programs utilizing the company’s versatile\nRNA medicines platform. Driven by the calling to “Reimagine Possible,”\nWave is leading the charge toward a world in which human potential is no\nlonger hindered by the burden of disease. Wave is headquartered in Cambridge,\nMA. For more information on Wave’s science, pipeline and people, please\nvisit www.wavelifesciences.com and follow Wave on X\n(https://www.globenewswire.com/Tracker?data=DiyzcCd5HX_SDV5g-hKDJK1jw-z1GbkHR69lkZ64ehZLKRrgrXOCVjdFk1MSqbWnS8yIOrf9OvW2e0UWYyrAyw==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=ANUFdTRT8JD8GIog3h2YboGD8SIAf1rLEzn1bnmLimMnmZmtkVMkSwkPU3td5Vr_WTUx0MxWZkAhfkkaRR0X7MCY7VMSE6G0WgdL5O2In7pvnFYEhCghWMnLyMRfRynV).\n\nContact:\nKate Rausch\nVP, Corporate Affairs and Investor Relations\n+1 617-949-4827\n\nInvestors:\nJames Salierno\nDirector, Investor Relations\n+1 617-949-4043\nInvestorRelations@wavelifesci.com\n\nMedia:\nKatie Sullivan\nSenior Director, Corporate Communications\n+1 617-949-2936\nMediaRelations@wavelifesci.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9gcm9l-20261013","title":"Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference","author":"Globe Newswire","ticker":"WVE","created":"2026-10-13T12:30:00.158Z","tickers":["WVE"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences,\nInc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health,\ntoday announced that Paul Bolno, MD, MBA, President and Chief Executive\nOfficer, is scheduled to participate in the “RNA Medicines: Next-Generation\nRNA Therapeutics” panel at Chardan’s 10(th) Annual Healthcare Conference\nin New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET.\n\nA live webcast of the panel can be accessed by visiting “Investor Events”\non the Investors section of the Wave Life Sciences website:\nhttps://ir.wavelifesciences.com/events-publications/events. A replay of this\npanel will be archived and available on the site for a limited time following\nthe event.\n\nAbout Wave Life Sciences\nWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health.\nWave’s PRISM® platform combines multiple RNA medicine modalities, chemistry\ninnovation, and deep insights in human genetics to deliver scientific\nbreakthroughs that treat both rare and common disorders. Its toolkit of\nRNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers),\nprovides Wave with unmatched capabilities for designing and sustainably\ndelivering candidates that optimally address disease biology. Wave’s\npipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency\n(WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes\nclinical programs in Duchenne muscular dystrophy and Huntington’s disease,\nas well as several preclinical programs utilizing the company’s versatile\nRNA medicines platform. Driven by the calling to “Reimagine Possible,”\nWave is leading the charge toward a world in which human potential is no\nlonger hindered by the burden of disease. Wave is headquartered in Cambridge,\nMA. For more information on Wave’s science, pipeline and people, please\nvisit www.wavelifesciences.com and follow Wave on X\n(https://www.globenewswire.com/Tracker?data=DiyzcCd5HX_SDV5g-hKDJK1jw-z1GbkHR69lkZ64ehZLKRrgrXOCVjdFk1MSqbWnS8yIOrf9OvW2e0UWYyrAyw==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=ANUFdTRT8JD8GIog3h2YboGD8SIAf1rLEzn1bnmLimMnmZmtkVMkSwkPU3td5Vr_WTUx0MxWZkAhfkkaRR0X7MCY7VMSE6G0WgdL5O2In7pvnFYEhCghWMnLyMRfRynV).\n\nContact:\nKate Rausch\nVP, Corporate Affairs and Investor Relations\n+1 617-949-4827\n\nInvestors:\nJames Salierno\nDirector, Investor Relations\n+1 617-949-4043\nInvestorRelations@wavelifesci.com\n\nMedia:\nKatie Sullivan\nSenior Director, Corporate Communications\n+1 617-949-2936\nMediaRelations@wavelifesci.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T12:30:00.195186234Z","server_sent_at_ms":1791894600195},"received_at":"2026-10-13T12:30:00.325Z","source_url":null},"analysis":{"id":"155840","press_release_id":"167546","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Wave Life Sciences CEO Paul Bolno will participate in an RNA medicines panel at Chardan's 10th Annual Healthcare Conference in New York on October 20, 2026 at 9:45 a.m. ET.\n\nA live webcast will be available on the company's investor relations site, with an archived replay afterward.\n\nThe announcement contains no new clinical or financial data; it is a routine investor-outreach event notice.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance notice -- suppress unless panel remarks surface new pipeline data."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Paul Bolno","role":"President and CEO"},{"name":"Kate Rausch","role":"VP, Corporate Affairs and Investor Relations"},{"name":"James Salierno","role":"Director, Investor Relations"},{"name":"Katie Sullivan","role":"Senior Director, Corporate Communications"}],"products":["PRISM","WVE-007","WVE-006","WVE-008"],"companies":[{"name":"Wave Life Sciences, Inc.","ticker":"WVE"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference panel participation announcement with no new financial, clinical, or strategic information."},"tickerRelevance":{"others":[],"primary":"WVE"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-participation-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Wave Life Sciences CEO Paul Bolno will participate in an RNA medicines panel at Chardan's 10th Annual Healthcare Conference in New York on October 20, 2026 at 9:45 a.m. ET.\n\nA live webcast will be available on the company's investor relations site, with an archived replay afterward.\n\nThe announcement contains no new clinical or financial data; it is a routine investor-outreach event notice.","key_figures":{},"named_entities":{"people":[{"name":"Paul Bolno","role":"President and CEO"},{"name":"Kate Rausch","role":"VP, Corporate Affairs and Investor Relations"},{"name":"James Salierno","role":"Director, Investor Relations"},{"name":"Katie Sullivan","role":"Senior Director, Corporate Communications"}],"products":["PRISM","WVE-007","WVE-006","WVE-008"],"companies":[{"name":"Wave Life Sciences, Inc.","ticker":"WVE"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:30:04.611Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-participation-notice","issuerAuthored":true}},"durationMs":4254,"modelName":"glm-5.3-flashx"}}